DONALDSON Co INCDCI
DONALDSON Co INC Goodwill & Intangibles Disclosure
Note 6. Goodwill and Intangible Assets
Goodwill
The Company allocates goodwill to reporting units within its Mobile Solutions, Industrial Solutions and Life Sciences segments. There were no dispositions or impairment charges recorded during the years ended July 31, 2025, 2024 and 2023. Goodwill is assessed for impairment annually during the third quarter of the fiscal year, or more frequently if events or changes in circumstances indicate the asset may be impaired. The Company performed its annual impairment assessment during the third quarter of fiscal 2025 and did not record any impairment as a result of this assessment.
Goodwill by reportable segment was as follows (in millions):
| Mobile Solutions Segment | Industrial Solutions Segment | Life Sciences Segment | Total Goodwill | ||||||||||||||||||||
| Balance as of July 31, 2023 | $ | 25.5 | $ | 289.1 | $ | 166.5 | $ | 481.1 | |||||||||||||||
| Goodwill acquired | — | 1.9 | — | 1.9 | |||||||||||||||||||
| Purchase price adjustments | — | — | (1.1) | (1.1) | |||||||||||||||||||
| Foreign exchange translation | (0.1) | (1.1) | (2.3) | (3.5) | |||||||||||||||||||
| Balance as of July 31, 2024 | $ | 25.4 | $ | 289.9 | $ | 163.1 | $ | 478.4 | |||||||||||||||
| Goodwill acquired | — | 3.2 | — | 3.2 | |||||||||||||||||||
| Foreign exchange translation | — | 5.1 | 6.9 | 12.0 | |||||||||||||||||||
| Balance as of July 31, 2025 | $ | 25.4 | $ | 298.2 | $ | 170.0 | $ | 493.6 | |||||||||||||||
Intangible Assets
Intangible asset classes were as follows (in millions):
Year Ended July 31, 2025 | |||||||||||||||||||||||
| Weighted Amortizable Life (in Years) | Gross Carrying Amount | Accumulated Amortization | Net | ||||||||||||||||||||
| Customer relationships | 8.5 | $ | 74.7 | $ | (43.7) | $ | 31.0 | ||||||||||||||||
| Trademarks | 6.7 | 3.8 | (2.0) | 1.8 | |||||||||||||||||||
Technology and patents | 16.6 | 82.9 | (19.1) | 63.8 | |||||||||||||||||||
| Non-compete agreements | 2.9 | 2.5 | (1.7) | 0.8 | |||||||||||||||||||
| Total intangible assets | $ | 163.9 | $ | (66.5) | $ | 97.4 | |||||||||||||||||
| Year Ended July 31, 2024 | |||||||||||||||||||||||
| Weighted Amortizable Life (in Years) | Gross Carrying Amount | Accumulated Amortization | Net | ||||||||||||||||||||
| Customer relationships | 9.4 | $ | 77.4 | $ | (39.9) | $ | 37.5 | ||||||||||||||||
| Trademarks | 8.1 | 14.2 | (3.8) | 10.4 | |||||||||||||||||||
Technology and patents | 16.7 | 142.4 | (20.4) | 122.0 | |||||||||||||||||||
| Non-compete agreements | 2.7 | 3.9 | (1.9) | 2.0 | |||||||||||||||||||
| Total intangible assets | $ | 237.9 | $ | (66.0) | $ | 171.9 | |||||||||||||||||
In the third quarter of fiscal 2025, the Company identified a triggering event related to certain asset groups and performed a valuation of certain long-lived intangible assets in accordance with ASC 360, Impairment and Disposal of Long-Lived Assets. The Company used a discounted cash flow analysis to estimate the fair value of each long-lived asset group. Estimates and assumptions are utilized in the valuations, including discounted projected cash flows, earnings before interest, taxes, depreciation and amortization margins, terminal value growth rates, revenue growth rates, discount rates and the determination of comparable publicly traded companies. As a result of the valuation, the Company recorded $62.0 million of impairment expense related to intangible assets in the Company’s bioprocessing businesses within the Life Sciences segment, including $53.1 million of impairment expense related to technology and patents, $7.7 million of impairment expense related to trademarks, $1.0 million of impairment expense related to customer relationships and $0.2 of impairment expense related to non-compete agreements. The impairment expense was included in loss on impairment of intangible assets in the Consolidated Statements of Earnings. Of the impairment expense, $46.6 million was related to Univercells Technologies, reflecting lower-than-anticipated bioprocessing capital spending, particularly for early-stage assets, while drug development timelines are longer than previously anticipated. The remaining $15.4 million of impairment expense was related to Solaris as market demand for industrial bioreactors had significantly declined.
The Company recognized a foreign currency translation gain of $3.0 million in fiscal 2025 and a translation loss of $1.4 million in fiscal 2024.
Intangible asset amortization expense was $13.9 million, $15.7 million and $11.4 million for the fiscal 2025, 2024 and 2023, respectively and is included in operating expenses in the Consolidated Statements of Earnings. Amortization expense relating to existing intangible assets as of July 31, 2025 was as follows (in millions):
| 2026 | $ | 9.4 | ||||||
| 2027 | 9.0 | |||||||
| 2028 | 8.6 | |||||||
| 2029 | 7.5 | |||||||
| 2030 | 7.1 | |||||||
| Thereafter | 55.8 | |||||||
| Total amortization expense | $ | 97.4 | ||||||
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Sep 26, 2025 | Showing above |
| 2024 | Sep 27, 2024 | |
| 2023 | Sep 22, 2023 | |
| 2022 | Sep 23, 2022 | |
| 2021 | Sep 24, 2021 | |
| 2020 | Sep 25, 2020 | |
| 2019 | Sep 27, 2019 | |
| 2018 | Oct 1, 2018 | |
| 2017 | Sep 22, 2017 | |
| 2016 | Sep 23, 2016 | |
| 2015 | Nov 10, 2015 | |
About Goodwill & Intangibles Disclosures
Goodwill and intangible asset disclosures reveal the premium paid in acquisitions and how management assesses whether that premium retains its value. Since goodwill is no longer amortized under US GAAP, the annual impairment test is the only mechanism that adjusts carrying values downward — making the assumptions behind that test critically important for investors.
Key signals: a history of goodwill impairments suggests management consistently overpays for acquisitions. Watch the gap between reporting unit fair value and carrying amount — when fair value exceeds carrying amount by less than 10-20%, a small decline in business performance could trigger a write-down. For finite-lived intangibles, examine useful life assumptions across customer relationships, technology, and trade names; aggressive estimates inflate near-term earnings. Compare total intangibles-to-total-assets ratios against peers to assess acquisition dependency. Rising goodwill as a percentage of equity can signal balance sheet fragility.